Restricted accessResearch articleFirst published online 2022-6
Methodological standards for using the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) in cancer clinical trials
Di MaioMGalloCLeighlNB, et al. Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. J Clin Oncol2015; 33(8): 910–915.
2.
FrommeEKEilersKMMoriM, et al. How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J Clin Oncol2004; 22(17): 3485–3490.
3.
LaugsandEASprangersMAGBjordalK, et al. Health care providers underestimate symptom intensities of cancer patients: a multicenter European study. Health Qual Life Outcomes2010; 8: 104.
4.
BaschE. The missing voice of patients in drug-safety reporting. N Engl J Med2010; 362(10): 865–869.
5.
AtkinsonTMLiYCoffeyCW, et al. Reliability of adverse symptom event reporting by clinicians. Qual Life Res2012; 21(7): 1159–1164.
6.
BaschEReeveBBMitchellSA, et al. Development of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst2014; 106(9): dju244.
7.
DueckACMendozaTRMitchellSA, et al. Validity and reliability of the US National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). JAMA Oncol2015; 1(8): 1051–1059.
8.
BaschERogakLJDueckAC. Methods for implementing and reporting patient-reported outcome (PRO) measures of symptomatic adverse events in cancer clinical trials. Clin Ther2016; 38(4): 821–830.
9.
MendozaTRDueckACBennettAV, et al. Evaluation of different recall periods for the US National Cancer Institute’s PRO-CTCAE. Clin Trials2017; 14(3): 255–263.
10.
King-KallimanisBBhatnagarVHorodniceanuEG, et al. Timing is everything: the importance of patient-reported outcome assessment frequency when characterizing symptomatic adverse events. Clin Trials this issue.
